Skip to main content

ResMed Inc. (RMD) Stock Analysis

Recovery setup

Buy WaitDEATH CROSS (EXEMPT)Moderate Confidence

Healthcare · Medical Instruments & Supplies

Wait for pullback to $200.99. Weak momentum — blocks BUY_NOW at $207.74. Engine's entry $200.99 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Below 200-MA, MA slope -2.7%/30d (confirmed downtrend).

ResMed develops and sells cloud-connected medical devices and software for sleep apnea, COPD, and chronic respiratory conditions through its Sleep and Breathing Health segment, plus Residential Care Software for HME/home health providers. With 10,600+ employees selling in 140+... Read more

$207.74+20.3% A.UpsideScore 6.2/10#2 of 25 Medical Instruments & Supplies
QualityF-score9 / 9FCF yield4.80%
IncomeYield1.16%(5y avg 0.84%)Payout22.47%sustainable
Entry $200.99(Atr Pullback Sticky)Stop $189.58Target $243.54(analyst − 10%)A.R:R 3.1:1Setup A.R:R 3.9:1
Analyst target$270.60+30.3%15 analysts
$243.54our TP
$207.74price
$270.60mean
$180
$340

Wait for pullback to $200.99. Weak momentum — blocks BUY_NOW at $207.74. Engine's entry $200.99 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Below 200-MA, MA slope -2.7%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 44. Wide-moat business. Accumulate on weakness. Score 6.2/10, moderate confidence.

Passes 9/11 gates (positive momentum, favorable risk/reward ratio, clean insider activity, positive momentum, no SEC red flags, news events none recent, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.

Val6.4Qual9.2Grw4.7Mom5.1Sent7.1Ins5.0Peer6.2Tech5.1Risk5.36.2OVERALL

Recent Developments — ResMed Inc.

Material events (past 30 days)

  • Apr 30, 2026 MEDIUM Item 5.02: CFO Brett Sandercock retiring effective May 4, 2026, transitioning to Special Advisor through December 2027. Aaron Bloomer, formerly CFO of Exact Sciences, appointed CFO effective May 4, 2026. No disagreement cited.

Latest news

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
V7 flight-to-quality bonus: +0.5 (Q=9.2 in RISK_OFF)
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (3/4)
Risks
Below 200-MA, MA slope -2.7%/30d (confirmed downtrend)

Key Metrics

P/E (TTM)20.0
P/E (Fwd)17.0
Mkt Cap$30.1B
EV/EBITDA13.8
Profit Mgn27.4%
ROE25.2%
Rev Growth10.8%
Beta0.84
Dividend1.16%
Rating analysts26

Quality Signals

Piotroski F9/9MoatWideCompounder✓

Options Flow

P/C1.32bearish
IV39%normal
Max Pain$145-30.2% vs spot

Material Events(8-K, last 90d)

  • 2026-04-30Item 5.02MEDIUM
    CFO Brett Sandercock retiring effective May 4, 2026, transitioning to Special Advisor through December 2027. Aaron Bloomer, formerly CFO of Exact Sciences, appointed CFO effective May 4, 2026. No disagreement cited.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 ceiling hit

GatesMomentum 5.1<5.5 (soft — BUY_NOW allowed but watch)Death cross exempted (quality + momentum high enough)Momentum 5.1>=4.5A.R:R 3.1 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 78d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Moderate
RSI
44 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $198.02Resistance $223.26

Price Targets

$190
$201
$244
A.Upside+17.2%
A.R:R3.1:1
Setup A.R:R (at entry)3.9:1

Position Sizing

ConvictionHigh conviction
Suggested %1.5%
Max %2.9%
RegimeRisk-Off

Analyst Consensus

Analysts26
Consensus3.7/5
Avg Target$271

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-08-06 (78d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is RMD stock a buy right now?

Wait for pullback to $200.99. Weak momentum — blocks BUY_NOW at $207.74. Engine's entry $200.99 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risk: Below 200-MA, MA slope -2.7%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 44. Wide-moat business. Accumulate on weakness. Target $243.54 (+17.2%), stop $189.58 (−9.6%), Setup A.R:R 3.9:1. Score 6.2/10, moderate confidence.

What is the RMD stock price target?

Take-profit target: $243.54 (+20.3% upside). Target $243.54 (+17.2%), stop $189.58 (−9.6%), Setup A.R:R 3.9:1. Stop-loss: $189.58.

What are the risks of investing in RMD?

Below 200-MA, MA slope -2.7%/30d (confirmed downtrend).

Is RMD overvalued or undervalued?

ResMed Inc. trades at a P/E of 20.0 (forward 17.0). TrendMatrix value score: 6.4/10. Verdict: Buy (Wait for Entry).

What do analysts say about RMD?

26 analysts cover RMD with a consensus score of 3.7/5. Average price target: $271.

What does ResMed Inc. do?ResMed develops and sells cloud-connected medical devices and software for sleep apnea, COPD, and chronic respiratory...

ResMed develops and sells cloud-connected medical devices and software for sleep apnea, COPD, and chronic respiratory conditions through its Sleep and Breathing Health segment, plus Residential Care Software for HME/home health providers. With 10,600+ employees selling in 140+ countries, ~64% of net revenues come from the U.S.

Related stocks: WST (West Pharmaceutical Services, I) · MMSI (Merit Medical Systems, Inc.) · TFX (Teleflex Incorporated) · NVST (Envista Holdings Corporation) · ISRG (Intuitive Surgical, Inc.)